Table 2.
Descriptive statistics of included patients in both groups
| DEB-TACE | cTACE | p-value | |
|---|---|---|---|
| Number of patients | 17 | 26 | |
| Number of procedures | 25 | 76 | |
| Age, years (mean ± SEM) | 67.76±3.05 | 68.35±2.42 | 0.88 |
| Gender | |||
| Male | 14 | 24 | |
| Female | 3 | 2 | |
| Etiology | |||
| Unknown/noncirrhotic | 5 | 10 | |
| ALD | 7 | 4 | |
| HCV | 2 | 3 | |
| HBV | 1 | 4 | |
| NASH | 2 | 3 | |
| Other | 0 | 2 | |
| Number of tumors | |||
| Multifocal | 2 | 12 | |
| Two lesions | 1 | 6 | 0.04 |
| Single lesion | 14 | 8 | |
| Size of tumor in mm (mean ± SEM) | 55.35±7.44 | 75.85±7.25 | 0.065 |
| Procedure per patient (mean ± SEM) | 1.43±0.16 | 3.03±0.33 | 0.0007 |
| Follow-up in months | 12.8 | 17.6 | 0.13 |
| Disease response (%) mRECIST | |||
| SD (%) | 10 | 20 | |
| PD (%) | 30 | 40 | |
| PR (%) | 15 | 30 | |
| CR (%) | 45 | 10 | |
| Inpatient stay, days (mean ± SEM) | 2.81±0.5 | 2.37±0.11 | 0.21 |
| Complications | 7/25 | 6/76 | 0.16 |
| 30-day mortality | 1 | 1 |
Abbreviations: ALD, alcohol related liver disease; CR, complete response; cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting beads transarterial chemoembolization; HBV, hepatitis B virus; HCV, hepatitis C virus; mRECIST, Modified Response Evaluation Criteria In Solid Tumors; NASH, nonalcoholic steatohepatitis; PD, progressive disease; PR, partial response; SD, stable disease; SEM, standard error of mean.